Search PubMed⌕ Search

Biomedical subjects

M J Webb

Publications and source records attributed to M J Webb.

At least 91 records · Page 5Linked to original sources
PubMed1977

Phase II evaluation of cytembena (NSC-104801) in patients with advanced ovarian carcinoma resistant to alkylating agents: brief communication.

Seventeen patients with stages III and IV alkylating agent-resistant ovarian carcinomas were treated with cytembena, which was given in doses of 200 mg/m2 twice daily for 5 consecutive days every 5 weeks. Sixteen patients completed at least one course of treatment; 11 of them experienced objective progression of disease or failed to continue treatment because of a continuing symptomatic deterioration within the first two treatment cycles. Three patients remained objectively stable after two courses of treatment, but were symptomatically worse and stopped treatment for that reason. Another patient experienced progression after three courses, and the final patient voluntarily withdrew after three courses. No objective regression of disease occurred during treatment with cytembena. Nausea and vomiting occurred at some time in all except 1 patient, and 3 patients experienced mild diarrhea. Two patients had alopecia.

Acrylates↗
PubMed1977

Management of the pelvic floor after pelvic exenteration.

At the Mayo Clinic, 198 exenterative operations were performed from 1950 through 1971. Although the 5-year survival rate of all patients was 33%, bowel obstruction occurred in 11.6% of patients and intestinal fistula formation in 12.6%. The majority of patients with these complications had had previous pelvic irradiation. The difficulty in dealing with the large raw area in the pelvis is discussed with a review of the various methods that have been tried to date to reperitonealize the pelvis and thereby, it is hoped, prevent adhesions or fistula formation.

Animals↗
PubMed1977

Trisomy 5: delineation of clinical features.

Partial trisomy for the short arm of chromosome No. 5 appears to result in an identifiable syndrome. Major features include characteristic facial appearance, mental and growth retardation, seizures, and an excess of ulnar loops. Less certain features may include strabismus and an absence of major congenital malformations. The translocation present in this family from the short arm of chromosome No. 5 to the short arm of No. 4 has, to the best of our knowledge, not been reported previously [6].

Adult↗
PubMed1976

Outpatient diagnostic aspiration curettage.

A series of 250 patients underwent aspiration curettage; 206 of the 250 underwent the procedure in the office without anesthesia. Patient acceptance of the method was good. Hysterectomy or follow-up dilatation and curettage within 24 hours in 97 patients revealed that the diagnosis was correct in 91% of the cases. The method provides an excellent endometrial specimen for histologic examination, has little risk for the patient, and saves considerable time and cost.

Adolescent↗
PubMed1975

Exenterative operations: experience with 198 patients.

In a series of 198 exenterative operations performed at the Mayo Clinic for various pelvic malignant lesions, a 5 year survival rate of 33 per cent was obtained. This rate is commendable, since almost 80 per cent of the operations were accomplished for recurrent malignancy. The diminished over-all operative mortality rate of 8.1 per cent, a reduction from 13.5 per cent (1950 through 1962) to 3 per cent (1963 through 1971), is attributed to better methods of urinary diversion and to better management of fluid replacement and of infectious complications. Major complications, excepting bowel fistula and obstruction, now can be controlled reasonably well. When more conservative and equally curative methods of therapy have been exhausted, all patients with pelvic malignancy (whether primary in cervix, vagina, bladder, urethra, rectum, or vulva) should be considered potential candidates for exenteration.

Adenocarcinoma↗
PubMed1975

Cancer metastatic to the ovary: factors influencing survival.

In the period 1950 through 1966, 357 patients with cancer metastatic to the ovaries were treated at the Mayo Clinic. The majority of primary tumors arose in the gastrointestinal tract. Factors influencing survival included the site of the primary cancer, histologic grade of the neoplasm, menstrual status, and the type of treatment. Patients whose cancers originated in the genital tract had the lowest mean death rate. Although analyses of survival confirm the observation that cancer metastatic to the ovaries has a poor overall prognosis, 21 of the 357 patients were still living at 10 years and 7 of these patients survived for at least 20 years. The continued development of improved technics of radiation therapy and of more effective chemotherapeutic agents should facilitate intensive therapy for patients with metastatic cancer of the ovaries and result in improved survival.

Adenocarcinoma↗